EN DE
Watch Gongwin Biopharm Holdings Co. Ltd. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Gongwin Biopharm Holdings Co. Ltd. (6617) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Gongwin Biopharm Holdings Co. Ltd. stock TWD 62.66, price TWD 119, that is 47.1% below the price, quality 44 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare TW

GB Gongwin Biopharm Holdings Co. Ltd. logo Thin data Nov 10, 2026

Gongwin Biopharm Holdings Co. Ltd.

6617 · TWO
Very expensive, weak quality

Our calculation puts a fair price 47% below what the stock costs today.

Ranks above peers (4/6)
Revenue last quarter +45% vs. a year ago.
Quality 44/100
Expensive Growth (revenue 3y +217.1 %/yr in TWD)
Fair value 62.66 TWD · Strongly overvalued
Negative free cash flow
Narrow moat 12/100 · thin data
Thin data
Estimate
Watch Gongwin Biopharm Holdings Co. Ltd. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

433.00 TWD 60.20 TWD Fair Value 62.66 TWD Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range 60.20 TWD – 433.00 TWD · fair‑value band 46.99 TWD – 78.32 TWD · the 118.50 TWD price screens above the 62.66 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Gongwin Biopharm Holdings Co. in your weekly email

Every Wednesday you see whether Gongwin Biopharm Holdings Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Gongwin Biopharm Holdings Co., Ltd., a clinical-stage biopharmaceutical company, develops anticancer drugs in Hong Kong, China, and Singapore.

Show moreShow less

It is developing PTS302, which has completed Phase III clinical trials for the treatment of lung cancer; PTS100, which is in Phase II clinical trials for the treatment of hepatocellular carcinoma; PTS02, which is in Phase I clinical trials for the treatment of adenoid cystic carcinoma; and PTS500 for the treatment of malignant pleural effusion.

The company also develops animal medicines; engaged in the pet medical business; and wholesale and retail of the medical equipment. Gongwin Biopharm Holdings Co., Ltd. was founded in 2014 and is based in Taipei, Taiwan.

Stock analysis

Gongwin Biopharm Holdings Co. Ltd. (6617) currently trades at 118.50 TWD, while our estimate is 62.66 TWD, 47% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 46.99 TWD (bear) to 78.32 TWD (bull), the price of 118.50 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 44/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Gongwin Biopharm Holdings Co. Ltd. reported revenue of 36.4M TWD in FY2025 versus 1.1M TWD in FY2021, a compound +137.6%/yr. Reported net income was −114M TWD in FY2025.

Key figures

Market cap 14.5B TWD (≈ $443M) Small · EPS (TTM) −1.27 TWD · Return on equity −7.4% · Return on assets (EBIT) −9.5% (5-year average) · Operating margin −485% · Revenue (TTM) 42.2M TWD · Revenue growth (YoY) +45.1% · Free cash flow −138M TWD.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (low confidence).

What moves the price

The share trades about 17% below its 52-week high and 97% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −47%, 6617 screens richer than that median.

Fair Value

Bear 46.99 TWD Fair Value 62.66 TWD Bull 78.32 TWD
Price 118.50 TWD · Downside -47.1%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 44/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 1
How much profit the company makes from its sales and capital
Quality Growth 50
Are margins and returns getting better?
Cashflow 15
Do the profits arrive as real cash?
Financial strength 99
Debt, balance sheet and risk of trouble
Investment 25
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 86
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 66
Distance to the 52-week high, does not count
New shares 78
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+13.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+217.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−10,571.0% (2021) → −573.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

6617 screens overvalued: fair value 47% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Gongwin Biopharm Holdings Co. Ltd. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 3/5 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 44 · Above median
Fair Value upside −47.1% · Bottom 25%
Profitability
Return on assets −4.1% · Above median
Growth and dividend
Revenue growth (quarter YoY) 45.1% · Top 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 5.74× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 20

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs 6617
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs 6617
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs 6617
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs 6617
argenx SE ARGX $971.55 $908.40 −7% vs 6617
CSL Limited CSL A$201.68 A$181.40 −10% vs 6617
Moderna, Inc MRNA $250.83 $158.70 −37% vs 6617
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs 6617
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs 6617
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs 6617

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Gongwin Biopharm Holdings Co. Ltd.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Gongwin Biopharm Holdings Co. Ltd. Fair Value". https://www.fairvalue-calculator.com/stock/6617

Frequently asked questions

Is Gongwin Biopharm Holdings Co. Ltd. (6617) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is 62.66 TWD versus a price of 118.50 TWD, about 47% lower (overvalued).
What is the fair value of 6617?
Our estimate for Gongwin Biopharm Holdings Co. Ltd. is 62.66 TWD (as of Nov 10, 2026), built from audited fundamentals. The current price: 118.50 TWD.
What is the quality score of 6617?
Gongwin Biopharm Holdings Co. Ltd. has a Quality Score of 44/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Gongwin Biopharm Holdings Co. Ltd. (6617)?
Our calculated price target is the estimate of 62.66 TWD (as of Nov 10, 2026). Cautious scenario 46.99 TWD, optimistic scenario 78.32 TWD. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Gongwin Biopharm Holdings Co. Ltd. stock forecast for 2026?
Our estimate puts fair value at 62.66 TWD, about 47% lower versus a price of 118.50 TWD (overvalued). Cautious scenario 46.99 TWD, optimistic scenario 78.32 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of Gongwin Biopharm Holdings Co. Ltd. (6617)?
Gongwin Biopharm Holdings Co. Ltd. reported trailing-twelve-month revenue of about 42.2M TWD (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Gongwin Biopharm Holdings Co. Ltd. (6617)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Gongwin Biopharm Holdings Co. Ltd. it is 62.66 TWD per share (as of Nov 10, 2026), against a price of 118.50 TWD.
Is Gongwin Biopharm Holdings Co. Ltd. stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 6617 trades above its calculated fair value: price 118.50 TWD, fair value 62.66 TWD, a gap of about −47% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6617?
No. The price is what the market pays today (118.50 TWD); the fair value is what the company's own numbers justify (62.66 TWD). For Gongwin Biopharm Holdings Co. Ltd. the two are 55.84 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is Gongwin Biopharm Holdings Co. Ltd. worth?
The market values Gongwin Biopharm Holdings Co. Ltd. at about 14.5B TWD (market capitalisation, as of Nov 10, 2026). Per share that is 118.50 TWD; our models calculate a fair value of 62.66 TWD per share.
What do the bullish and bearish scenarios say about 6617?
Our models span a range for Gongwin Biopharm Holdings Co. Ltd.: cautious scenario 46.99 TWD, base 62.66 TWD, optimistic 78.32 TWD per share (as of Nov 10, 2026, price 118.50 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Gongwin Biopharm Holdings Co. Ltd. (6617)?
Balance-sheet figures for Gongwin Biopharm Holdings Co. Ltd. (as of Nov 10, 2026): return on equity −7.4%. They feed the Quality Score of 44/100, which measures business quality independently of the share price.
How far is 6617 from its 52-week high?
Gongwin Biopharm Holdings Co. Ltd. trades at 118.50 TWD, about 17% below its 52-week high of 143.00 TWD and 97% above the low of 60.20 TWD (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of 62.66 TWD is for.
Which stocks are comparable to Gongwin Biopharm Holdings Co. Ltd.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Gongwin Biopharm Holdings Co. Ltd. stock attractive at the current price?
The data as of Nov 10, 2026: price 118.50 TWD, calculated fair value 62.66 TWD (−47%), Quality Score 44/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Gongwin Biopharm Holdings Co. Ltd. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Gongwin Biopharm Holdings Co. Ltd. (6617)?
The closing price on Nov 10, 2026 was 118.50 TWD. Our estimate is 62.66 TWD, about 47% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Gongwin Biopharm Holdings Co. Ltd. right now?
The price sits above even our optimistic bull case (78.32 TWD). The favourable scenario is already priced in. Weak quality (44/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Gongwin Biopharm Holdings Co. Ltd.

How large is the market capitalisation of Gongwin Biopharm Holdings Co. Ltd. (6617)?
The market capitalisation of Gongwin Biopharm Holdings Co. Ltd. is 14.5B TWD (≈ $443M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Gongwin Biopharm Holdings Co. Ltd. (6617)?
Earnings per share at Gongwin Biopharm Holdings Co. Ltd. are −1.27 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Gongwin Biopharm Holdings Co. Ltd. (6617)?
The return on equity (ROE) of Gongwin Biopharm Holdings Co. Ltd. is −7.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Gongwin Biopharm Holdings Co. Ltd. (6617)?
On an EBIT basis the return on assets of Gongwin Biopharm Holdings Co. Ltd. is −9.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Gongwin Biopharm Holdings Co. Ltd. (6617)?
The operating margin of Gongwin Biopharm Holdings Co. Ltd. is −485% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Gongwin Biopharm Holdings Co. Ltd. (6617)?
Revenue at Gongwin Biopharm Holdings Co. Ltd. is growing +45.1% versus a year earlier (3y avg +217%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Gongwin Biopharm Holdings Co. Ltd. (6617) generate?
The free cash flow of Gongwin Biopharm Holdings Co. Ltd. is −138M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch Gongwin Biopharm Holdings Co. Ltd. in the live analysis

One click puts Gongwin Biopharm Holdings Co. Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.